Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update.

Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM.

Clin Pharmacokinet. 2019 Oct;58(10):1237-1263. doi: 10.1007/s40262-019-00774-0. Review.

2.

Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.

Gini J, Amara A, Penchala SD, Back DJ, Else L, Egan D, Chiong J, Harri BI, Kabilis ED, Pama PP, Stephen M, Khoo SH.

Int J STD AIDS. 2019 Mar;30(4):371-377. doi: 10.1177/0956462418809749. Epub 2018 Nov 30.

PMID:
30501368
3.

Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.

van Seyen M, Smolders EJ, van Wijngaarden P, Drenth JPH, Wouthuyzen-Bakker M, de Knegt RJ, Honkoop P, El-Sherif O, Colbers A, Back DJ, Burger DM.

J Hepatol. 2019 Mar;70(3):552-554. doi: 10.1016/j.jhep.2018.10.010. Epub 2018 Nov 23. No abstract available.

PMID:
30473264
4.

Kidney Diseases Associated with Human Immunodeficiency Virus Infection.

Back DJ.

N Engl J Med. 2018 Apr 26;378(17):1654-5. doi: 10.1056/NEJMc1800396. No abstract available.

PMID:
29697922
5.

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Cirrincione LR, Penchala SD, Scarsi KK, Podany AT, Winchester LC, Back DJ, Khoo SH, Fletcher CV, Siccardi M, Else LJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 1;1084:106-112. doi: 10.1016/j.jchromb.2018.03.023. Epub 2018 Mar 12.

6.

Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.

Pushpakom SP, Adaikalakoteswari A, Owen A, Back DJ, Tripathi G, Kumar S, McTernan P, Pirmohamed M.

Diab Vasc Dis Res. 2018 May;15(3):233-242. doi: 10.1177/1479164118757924. Epub 2018 Feb 21.

7.

Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.

Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher CV, Lamorde M, Scarsi KK, Siccardi M.

J Antimicrob Chemother. 2018 Apr 1;73(4):1004-1012. doi: 10.1093/jac/dkx515.

8.

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study.

Amara AB, Else LJ, Carey D, Khoo S, Back DJ, Amin J, Emery S, Puls RL.

Ther Drug Monit. 2017 Dec;39(6):654-658. doi: 10.1097/FTD.0000000000000448.

PMID:
28953037
9.

In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.

Rajoli RKR, Back DJ, Rannard S, Meyers CF, Flexner C, Owen A, Siccardi M.

Clin Pharmacokinet. 2018 Feb;57(2):255-266. doi: 10.1007/s40262-017-0557-x.

10.

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Seden K, Gibbons S, Marzolini C, Schapiro JM, Burger DM, Back DJ, Khoo SH.

PLoS One. 2017 Mar 23;12(3):e0173509. doi: 10.1371/journal.pone.0173509. eCollection 2017.

11.

The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Neary M, Lamorde M, Olagunju A, Darin KM, Merry C, Byakika-Kibwika P, Back DJ, Siccardi M, Owen A, Scarsi KK.

Clin Pharmacol Ther. 2017 Sep;102(3):529-536. doi: 10.1002/cpt.667. Epub 2017 May 30.

12.

A call for a consortium for optimal management of drug-drug interactions in patient care.

Burger DM, Smolders EJ, Schapiro J, Drenth J, Back DJ.

Clin Pharmacol Ther. 2017 Sep;102(3):391-394. doi: 10.1002/cpt.648. Epub 2017 Mar 17.

PMID:
28160270
13.

Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.

Dezzutti CS, Else LJ, Yandura SE, Shetler C, Russo J, Back DJ, McGowan I.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2765-70. doi: 10.1128/AAC.00167-16. Print 2016 May.

14.

Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Scarsi KK, Darin KM, Nakalema S, Back DJ, Byakika-Kibwika P, Else LJ, Dilly Penchala S, Buzibye A, Cohn SE, Merry C, Lamorde M.

Clin Infect Dis. 2016 Mar 15;62(6):675-682. doi: 10.1093/cid/civ1001. Epub 2015 Dec 8.

15.

Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.

Back DJ, Burger DM.

Gastroenterology. 2015 Nov;149(6):1315-7. doi: 10.1053/j.gastro.2015.09.031. Epub 2015 Sep 28. No abstract available.

PMID:
26416328
16.

Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005-2009.

Savage EJ, Lowndes CM, Sullivan AK, Back DJ, Else LJ, Murphy G, Gill ON.

AIDS. 2016 Jan 2;30(1):145-9. doi: 10.1097/QAD.0000000000000868.

PMID:
26372479
17.

Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda.

Seden K, Merry C, Hewson R, Siccardi M, Lamorde M, Byakika-Kibwika P, Laker E, Parkes-Ratanshi R, Back DJ, Khoo SH.

J Antimicrob Chemother. 2015 Dec;70(12):3317-22. doi: 10.1093/jac/dkv259. Epub 2015 Aug 18.

18.

Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.

Lamorde M, Walimbwa S, Byakika-Kibwika P, Katwere M, Mukisa L, Sempa JB, Else L, Back DJ, Khoo SH, Merry C.

J Antimicrob Chemother. 2015 May;70(5):1482-6. doi: 10.1093/jac/dku575. Epub 2015 Feb 3.

PMID:
25652748
19.

Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.

Lamorde M, Schapiro JM, Burger D, Back DJ.

AIDS. 2014 Nov 13;28(17):2551-63. doi: 10.1097/QAD.0000000000000439. Review.

PMID:
25574958
20.

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M.

Clin Pharmacokinet. 2015 Jun;54(6):639-50. doi: 10.1007/s40262-014-0227-1.

21.

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.

Reynolds HE, Chrdle A, Egan D, Chaponda M, Else L, Chiong J, Back DJ, Khoo SH.

J Antimicrob Chemother. 2015 Feb;70(2):550-4. doi: 10.1093/jac/dku376. Epub 2014 Sep 26.

PMID:
25261424
22.

A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry.

Amara AB, Else LJ, Tjia J, Olagunju A, Puls RL, Khoo S, Back DJ.

Ther Drug Monit. 2015 Apr;37(2):220-8. doi: 10.1097/FTD.0000000000000127.

PMID:
25162217
23.

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry.

Else LJ, Tjia J, Jackson A, Penchala SD, Egan D, Boffito M, Khoo SH, Back DJ.

Bioanalysis. 2014;6(14):1907-21. doi: 10.4155/bio.14.59.

PMID:
25158963
24.

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.

Clin Pharmacol Ther. 2014 Sep;96(3):314-23. doi: 10.1038/clpt.2014.118. Epub 2014 May 26.

PMID:
24862215
25.

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S, Lambert JS.

HIV Med. 2014 Nov;15(10):604-10. doi: 10.1111/hiv.12164. Epub 2014 May 14.

26.

Abacavir forms novel cross-linking abacavir protein adducts in patients.

Meng X, Lawrenson AS, Berry NG, Maggs JL, French NS, Back DJ, Khoo SH, Naisbitt DJ, Park BK.

Chem Res Toxicol. 2014 Apr 21;27(4):524-35. doi: 10.1021/tx400406p. Epub 2014 Feb 26.

PMID:
24571427
27.

Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.

Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A.

Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23.

28.

Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.

Moss DM, Liptrott NJ, Curley P, Siccardi M, Back DJ, Owen A.

Antimicrob Agents Chemother. 2013 Nov;57(11):5612-8. doi: 10.1128/AAC.01421-13. Epub 2013 Sep 3.

29.

Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer.

Penchala SD, Tjia J, El Sherif O, Back DJ, Khoo SH, Else LJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:100-10. doi: 10.1016/j.jchromb.2013.06.013. Epub 2013 Jun 17.

PMID:
23831525
30.

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

Liptrott NJ, Curley P, Moss D, Back DJ, Khoo SH, Owen A.

J Antimicrob Chemother. 2013 Nov;68(11):2545-9. doi: 10.1093/jac/dkt225. Epub 2013 Jun 21.

31.

RXRγ gene variants are associated with HIV lipodystrophy.

Pushpakom SP, Owen A, Back DJ, Pirmohamed M.

Pharmacogenet Genomics. 2013 Aug;23(8):438-41. doi: 10.1097/FPC.0b013e328362cfc6.

PMID:
23759678
32.

Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.

Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, Lefèvre G, Back DJ, Khoo SH, Merry C.

AIDS. 2013 Mar 27;27(6):961-5. doi: 10.1097/QAD.0b013e32835cae3b.

PMID:
23698061
33.

Predicting intestinal absorption of raltegravir using a population-based ADME simulation.

Moss DM, Siccardi M, Back DJ, Owen A.

J Antimicrob Chemother. 2013 Jul;68(7):1627-34. doi: 10.1093/jac/dkt084. Epub 2013 Mar 20.

PMID:
23515248
34.

Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.

Meng X, Howarth A, Earnshaw CJ, Jenkins RE, French NS, Back DJ, Naisbitt DJ, Park BK.

Chem Res Toxicol. 2013 Apr 15;26(4):575-83. doi: 10.1021/tx4000107. Epub 2013 Mar 12.

PMID:
23448204
35.

Non-disclosure of HIV status in UK sexual health clinics--a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey.

Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G, Carne S, Back DJ, Gill ON.

Sex Transm Infect. 2013 Mar;89(2):120-1. doi: 10.1136/sextrans-2012-050801. Epub 2013 Feb 13.

PMID:
23408314
36.

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.

Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle M, Khoo SH, Back DJ, Owen A.

Antivir Ther. 2012;17(5):861-8. doi: 10.3851/IMP2095. Epub 2012 Apr 4.

37.

Divalent metals and pH alter raltegravir disposition in vitro.

Moss DM, Siccardi M, Murphy M, Piperakis MM, Khoo SH, Back DJ, Owen A.

Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6. doi: 10.1128/AAC.06407-11. Epub 2012 Mar 26.

38.

Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.

Siccardi M, DʼAvolio A, Rodriguez-Novoa S, Cuenca L, Simiele M, Baietto L, Calcagno A, Moss D, Bonora S, Soriano V, Back DJ, Owen A, Di Perri G.

Ther Drug Monit. 2012 Apr;34(2):232-5. doi: 10.1097/FTD.0b013e31824aa50a.

PMID:
22406652
39.

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.

Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19.

40.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.

Else LJ, Taylor S, Back DJ, Khoo SH.

Antivir Ther. 2011;16(8):1149-67. doi: 10.3851/IMP1919. Review.

PMID:
22155899
41.

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

Else LJ, Taylor S, Back DJ, Khoo SH.

Antivir Ther. 2011;16(8):1139-47. doi: 10.3851/IMP1918. Review.

PMID:
22155898
42.

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP.

Antimicrob Agents Chemother. 2012 Feb;56(2):816-24. doi: 10.1128/AAC.05186-11. Epub 2011 Nov 21.

43.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Liptrott NJ, Pushpakom S, Wyen C, Fätkenheuer G, Hoffmann C, Mauss S, Knechten H, Brockmeyer NH, Hopper-Borge E, Siccardi M, Back DJ, Khoo SH, Pirmohamed M, Owen A; German Competence Network for HIV/AIDS.

Pharmacogenet Genomics. 2012 Jan;22(1):10-9. doi: 10.1097/FPC.0b013e32834dd82e.

44.

IFN-γ 874A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patients.

Liptrott NJ, Egan D, Back DJ, Owen A.

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):442-5. doi: 10.1097/QAI.0b013e318236441c.

PMID:
21926633
45.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

46.

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.

Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, Khoo S, Pirmohamed M, Owen A.

J Infect Dis. 2011 Jul 1;204(1):145-53. doi: 10.1093/infdis/jir215.

47.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

48.

Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.

Else LJ, Lyons F, O'shea S, Costello S, Mullen J, Lechelt M, Dickinson L, Magaya V, Back DJ, de Ruiter A.

AIDS. 2011 Mar 13;25(5):722-5. doi: 10.1097/QAD.0b013e3283445700. No abstract available.

PMID:
21368593
49.

Adipogenic gene variants in patients with HIV-associated lipodystrophy.

Pushpakom SP, Owen A, Vilar FJ, Castro H, Dunn DT, Back DJ, Pirmohamed M.

Pharmacogenet Genomics. 2011 Feb;21(2):76-83. doi: 10.1097/FPC.0b013e328342a917.

PMID:
21178827
50.

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

Randell PA, Jackson AG, Boffito M, Back DJ, Tjia JF, Taylor J, Mandalia S, Moyle GJ.

Antivir Ther. 2010;15(8):1125-32. doi: 10.3851/IMP1675.

PMID:
21149919

Supplemental Content

Support Center